14 September 2018 - The UK could be “less interesting” to pharma and life sciences firms after Brexit, the CEO of Roche has said, citing uncertainty over drug regulations and an unwillingness to use expensive branded drugs as potential turn-offs.

Speaking to Reuters, Roche’s CEO Severin Schwan made his comments with only six months to go before the UK is due to leave the European Union.

There are no clear arrangements about drug regulations after Brexit, and NICE has just rejected Roche’s latest multiple sclerosis medicine Ocrevus in patients, the only approved treatment for the progressive form of the disease.

Read Pharmaphorum article